Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHL Peptide Vaccine in Advanced Renal Cell Carcinoma
NCT00001703Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 1998
- Primary completion
- Nov 2008
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mutant VHL peptide vaccine in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Primary endpoint: Percentage of Participants Who Generated an Immune Response at 30 months. Started Aug 1998; status: terminated.
02
Drugs
mutant VHL peptide vaccine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00001703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001703.